![Patrick Lucy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrick Lucy
Presidente presso DYADIC INTERNATIONAL, INC.
Patrimonio netto: 40 218 $ in data 30/06/2024
Profilo
Patrick K.
Lucy was the founder and had founded Pelican Inc in 2009, where he held the title of Chief Business Officer & Senior Vice President from 2017 to 2020.
He currently holds the position of President, Chief Executive Officer & Director at Lykan Bioscience LLC since 2021.
He is also the President & Chief Executive Officer at Roslin Cell Therapies Ltd.
and Chairman at Dyadic International, Inc. In his former positions, Mr. Lucy worked as the Director-Business Development at Collaborative BioAlliance Inc & Collaborative Smithfield Corp from 1999 to 2002.
He then served as the Director-Business Development at Dowpharma from 2002 to 2009.
He also worked as a Principal at The Dow Chemical Co. and Repligen Corp.
from 1991 to 1998.
Additionally, he was the Manager-Validation & Capital Project at Lonza Biologics Plc from 1996 to 1999.
Mr. Lucy obtained his undergraduate degree from Villanova University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
17/04/2024 | 27 174 ( 0.09% ) | 40 218 $ | 30/06/2024 |
Posizioni attive di Patrick Lucy
Società | Posizione | Inizio |
---|---|---|
DYADIC INTERNATIONAL, INC. | Presidente | 28/03/2024 |
Lykan Bioscience LLC
![]() Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | Amministratore Delegato | 01/04/2021 |
Roslin Cell Therapies Ltd.
![]() Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Amministratore Delegato | - |
Precedenti posizioni note di Patrick Lucy
Società | Posizione | Fine |
---|---|---|
PFENEX INC. | Amministratore Delegato | 03/08/2017 |
Dowpharma
![]() Dowpharma Chemicals: SpecialtyProcess Industries Dowpharma Manufactures and distributes chemical, pharmaceutical, and biopharmaceutical products. It offers nucleic acid medicines, peptides, and ChelaMed radiopharmaceutical products. The company is headquartered in Cambridge, UK. | Corporate Officer/Principal | 01/01/2009 |
Collaborative BioAlliance Inc & Collaborative Smithfield Corp
![]() Collaborative BioAlliance Inc & Collaborative Smithfield Corp Pharmaceuticals: MajorHealth Technology Part of Dow, Inc., Collaborative BioAlliance Inc & Collaborative Smithfield Corp is an American company that develops and manufactures biopharmaceutical drugs. The company is based in NY. Collaborative BioAlliance Inc & Collaborative Smithfield was acquired by The Dow Chemical Co., a SUB of Dow, Inc. from Engelhard Long Island, Inc. on November 17, 2000. | Corporate Officer/Principal | 01/01/2002 |
Lonza Biologics Plc
![]() Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | Corporate Officer/Principal | 01/01/1999 |
REPLIGEN CORPORATION | Corporate Officer/Principal | 01/01/1998 |
Formazione di Patrick Lucy
Villanova University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
REPLIGEN CORPORATION | Health Technology |
DYADIC INTERNATIONAL, INC. | Health Services |
Aziende private | 7 |
---|---|
Pelican Inc
![]() Pelican Inc BiotechnologyHealth Technology Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA. | Health Technology |
The Dow Chemical Co.
![]() The Dow Chemical Co. Chemicals: SpecialtyProcess Industries The Dow Chemical Co. engages in the manufacture and distribution of chemicals, plastics, industrial and agricultural products. It serves agriculture, automotive, building and construction, consumer, electronic materials, infrastructure, packaging, product finder and product safety industries. The company was founded by Herbert Henry Dow in 1897 and is headquartered in Midland, MI. | Process Industries |
Collaborative BioAlliance Inc & Collaborative Smithfield Corp
![]() Collaborative BioAlliance Inc & Collaborative Smithfield Corp Pharmaceuticals: MajorHealth Technology Part of Dow, Inc., Collaborative BioAlliance Inc & Collaborative Smithfield Corp is an American company that develops and manufactures biopharmaceutical drugs. The company is based in NY. Collaborative BioAlliance Inc & Collaborative Smithfield was acquired by The Dow Chemical Co., a SUB of Dow, Inc. from Engelhard Long Island, Inc. on November 17, 2000. | Health Technology |
Lonza Biologics Plc
![]() Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | Commercial Services |
Dowpharma
![]() Dowpharma Chemicals: SpecialtyProcess Industries Dowpharma Manufactures and distributes chemical, pharmaceutical, and biopharmaceutical products. It offers nucleic acid medicines, peptides, and ChelaMed radiopharmaceutical products. The company is headquartered in Cambridge, UK. | Process Industries |
Lykan Bioscience LLC
![]() Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | Health Technology |
Roslin Cell Therapies Ltd.
![]() Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Health Technology |
- Borsa valori
- Insiders
- Patrick Lucy